- -

Dynamic evaluation of neutrophil-to-lymphocyte ratio as prognostic factor in stage III non-small cell lung cancer treated with chemoradiotherapy

RiuNet: Institutional repository of the Polithecnic University of Valencia

Share/Send to

Cited by

Statistics

Dynamic evaluation of neutrophil-to-lymphocyte ratio as prognostic factor in stage III non-small cell lung cancer treated with chemoradiotherapy

Show full item record

Palomar-Abril, V.; Soria-Comes, T.; Tarazona Campos, S.; Ureste, MM.; Giner-Bosch, V.; Maiques, ICM. (2020). Dynamic evaluation of neutrophil-to-lymphocyte ratio as prognostic factor in stage III non-small cell lung cancer treated with chemoradiotherapy. Clinical & Translational Oncology. 22(12):2333-2340. https://doi.org/10.1007/s12094-020-02396-6

Por favor, use este identificador para citar o enlazar este ítem: http://hdl.handle.net/10251/161216

Files in this item

Item Metadata

Title: Dynamic evaluation of neutrophil-to-lymphocyte ratio as prognostic factor in stage III non-small cell lung cancer treated with chemoradiotherapy
Author: Palomar-Abril, V. Soria-Comes, T. Tarazona Campos, Sonia Ureste, M. M. Giner-Bosch, Vicent Maiques, I. C. M.
UPV Unit: Universitat Politècnica de València. Departamento de Estadística e Investigación Operativa Aplicadas y Calidad - Departament d'Estadística i Investigació Operativa Aplicades i Qualitat
Issued date:
Abstract:
[EN] Purpose Locally advanced non-small cell lung cancer (LA-NSCLC) is frequently treated with chemoradiotherapy (CRT). Despite the efforts, long-term outcomes are poor, and novel therapies have been introduced to improve ...[+]
Subjects: Non-small cell lung cancer , Neutrophil-to-lymphocyte ratio , Stage III , Chemoradiotherapy , Survival outcomes
Copyrigths: Cerrado
Source:
Clinical & Translational Oncology. (issn: 1699-048X )
DOI: 10.1007/s12094-020-02396-6
Publisher:
Springer-Verlag
Publisher version: https://doi.org/10.1007/s12094-020-02396-6
Type: Artículo

References

Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA Cancer J Clin. 2019;69:7–34. https://doi.org/10.3322/caac.21551.

Molina JR, Yang P, Cassivi SD, et al. Non–small cell lung cancer: epidemiology, risk factors, treatment, and survivorship. Epidemiology. 2019;1:584–94.

Goldstraw P, Chansky K, Crowley J, et al. The IASLC lung cancer staging project: proposals for revision of the TNM stage groupings in the forthcoming (eighth) edition of the TNM classification for lung cancer. J Thorac Oncol. 2016;11:39–51. https://doi.org/10.1016/j.jtho.2015.09.009. [+]
Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA Cancer J Clin. 2019;69:7–34. https://doi.org/10.3322/caac.21551.

Molina JR, Yang P, Cassivi SD, et al. Non–small cell lung cancer: epidemiology, risk factors, treatment, and survivorship. Epidemiology. 2019;1:584–94.

Goldstraw P, Chansky K, Crowley J, et al. The IASLC lung cancer staging project: proposals for revision of the TNM stage groupings in the forthcoming (eighth) edition of the TNM classification for lung cancer. J Thorac Oncol. 2016;11:39–51. https://doi.org/10.1016/j.jtho.2015.09.009.

Postmus PE, Kerr KM, Oudkerk M, et al. Early and locally advanced non-small-cell lung cancer (NSCLC): ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2017;28:12. https://doi.org/10.1093/annonc/mdx222.

Antonia SJ, Villegas A, Daniel D, et al. Durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer. N Engl J Med. 2017;377:1919–29. https://doi.org/10.1056/NEJMoa1709937.

Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144:646–74. https://doi.org/10.1016/j.cell.2011.02.013.

Federico A, Morgillo F, Tuccillo C, et al. Chronic inflammation and oxidative stress in human carcinogenesis. Int J Cancer. 2007;121:2381–6. https://doi.org/10.1002/ijc.23192.

Lee Y, Kim SH, Han JY, et al. Early neutrophil-to-lymphocyte ratio reduction as a surrogate marker of prognosis in never smokers with advanced lung adenocarcinoma receiving gefitinib or standard chemotherapy as first-line therapy. J Cancer Res Clin Oncol. 2012;138:2009–166. https://doi.org/10.1007/s00432-012-1281-4.

Minami S, Ogata Y, Ihara S, et al. Neutrophil-to-lymphocyte ratio predicts overall survival of advanced non-small cell lung cancer harboring mutant epidermal growth factor receptor. Orig Artic World J Oncol. 2017;8:180–7. https://doi.org/10.14740/wjon1069w.

Yin Y, Wang J, Wang X, et al. Prognostic value of the neutrophil to lymphocyte ratio in lung cancer: a meta-analysis. Clinics. 2015. https://doi.org/10.6061/clinics/2015(07)10.

Takeda T, Takeuchi M, Saitoh M, Takeda S. Neutrophil-to-lymphocyte ratios after 4 weeks of nivolumab administration as a predictive marker in patients with pretreated non-small-cell lung cancer: NLR in NSCLC 4 weeks after nivolumab. Thorac Cancer. 2018;9:1291–9. https://doi.org/10.1111/1759-7714.12838.

Soda H, Ogawara D, Fukuda Y, et al. Dynamics of blood neutrophil-related indices during nivolumab treatment may be associated with response to salvage chemotherapy for non-small cell lung cancer. Oncologist. 2019;10:341–6. https://doi.org/10.1111/1759-7714.12952.

Scilla KA, Bentzen SM, Lam VK, et al. Neutrophil-lymphocyte ratio is a prognostic marker in patients with locally advanced (stage IIIa and IIIb) non-small cell lung cancer treated with combined modality therapy. Oncologist. 2017;22:737–42. https://doi.org/10.1634/theoncologist.2016-0443.

Mirsadraee S, Oswal D, Alizadeh Y, et al. The 7th lung cancer TNM classification and staging system: review of the changes and implications. World J Radiol. 2012;4:128–34. https://doi.org/10.4329/wjr.v4.i4.128.

Blanco R, Maestu I, de la Torre MG, et al. A review of the management of elderly patients with non-small-cell lung cancer. Ann Oncol. 2015;26:451–63. https://doi.org/10.1093/annonc/mdu268.

Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45:228–47. https://doi.org/10.1016/j.ejca.2008.10.026.

Peng B, Wang Y-H, Liu Y-M, Ma L-X. Prognostic significance of the neutrophil to lymphocyte ratio in patients with non-small cell lung cancer: a systemic review and meta-analysis. Int J Clin Exp Med. 2015;8:3098–106.

Finn OJ. Immuno-oncology: understanding the function and dysfunction of the immune system in cancer. Ann Oncol. 2012;23:8–11. https://doi.org/10.1093/annonc/mds256.

Franceschi C, Campisi J. Chronic inflammation (inflammaging) and its potential contribution to age-associated diseases. J Gerontol A Biol Sci Med Sci. 2014;69:4–9. https://doi.org/10.1093/gerona/glu057.

Urabe M, Yamashita H, Watanabe T, Seto Y. Comparison of prognostic abilities among preoperative laboratory data indices in patients with resectable gastric and esophagogastric junction adenocarcinoma. World J Surg. 2018. https://doi.org/10.1007/s00268-017-4146-9.

Losada B, Guerra JA, Malón D, et al. Pretreatment neutrophil/lymphocyte, platelet/lymphocyte, lymphocyte/monocyte, and neutrophil/monocyte ratios and outcome in elderly breast cancer patients. Clin Transl Oncol. 2018. https://doi.org/10.1007/s12094-018-1999-9.

Gonzalez H, Hagerling C, Werb Z. Roles of the immune system in cancer: from tumor initiation to metastatic progression. Cancer. 2018. https://doi.org/10.1101/gad.314617.

Pawelec G. Immunosenescence and cancer. Biogerontology. 2017;18:717–21. https://doi.org/10.1007/s10522-017-9682-z.

Yao Y, Yuan D, Liu H, et al. Pretreatment neutrophil to lymphocyte ratio is associated with response to therapy and prognosis of advanced non-small cell lung cancer patients treated with first-line platinum-based chemotherapy. Cancer Immunol Immunother. 2013;62:471–9. https://doi.org/10.1007/s00262-012-1347-9.

Kiriu T, Yamamoto M, Nagano T, et al. The time-series behavior of neutrophil-to-lymphocyte ratio is useful as a predictive marker in non-small cell lung cancer. PLoS ONE. 2018;1:13. https://doi.org/10.1371/journal.pone.0193018.

Khunger M, Patil PD, Khunger A, et al. Post-treatment changes in hematological parameters predict response to nivolumab monotherapy in non-small cell lung cancer patients. PLoS ONE. 2018;1:11. https://doi.org/10.1371/journal.pone.0197743.

Tang H, Ma H, Peng F, et al. Prognostic performance of inflammation-based prognostic indices in locally advanced non-small-lung cancer treated with endostar and concurrent chemoradiotherapy. Mol Clin Ongol. 2016;4:801–6. https://doi.org/10.3892/mco.2016.796.

Tong YS, Tan J, Zhou XL, et al. Systemic immune-inflammation index predicting chemoradiation resistance and poor outcome in patients with stage III non-small cell lung cancer. J Transl Med. 2017;15:1–10. https://doi.org/10.1186/s12967-017-1326-1.

Topkan E, Bolukbasi Y, Ozdemir Y, et al. Prognostic value of pretreatment Glasgow prognostic score in stage IIIB geriatric non-small cell lung cancer patients undergoing radical chemoradiotherapy. J Geriat Oncol. 2018;10(4):567–72.

Nakaya A, Kurata T, Yoshioka H, et al. Neutrophil - to - lymphocyte ratio as an early marker of outcomes in patients with advanced non - small - cell lung cancer treated with nivolumab. Int J Clin Oncol. 2018;23:634–40. https://doi.org/10.1007/s10147-018-1250-2.

Putzu C, Cortinovis DL, Colonese F, et al. Blood cell count indexes as predictors of outcomes in advanced non-small-cell lung cancer patients treated with nivolumab. Cancer Immunol Immunother. 2018;67:1–5. https://doi.org/10.1007/s00262-018-2182-4.

Kang KH, Efird JT, Sharma N, et al. Prognostic potential of neutrophil-to-lymphocyte ratio and lymphocyte nadir in stage III non-small-cell lung cancer. Futur Oncol. 2017. https://doi.org/10.2217/fon-2017-0045.

Templeton AJ, Mcnamara MG, Šeruga B, et al. Prognostic role of neutrophil-to-lymphocyte ratio in solid tumors. Syst Rev Meta Anal. 2014;106:1. https://doi.org/10.1093/jnci/dju124.

Fei Xu, Pengliang Xu, Cui W, et al. Neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios may aid in identifying patients with non-small cell lung cancer and predicting tumor-node-metastasis stages. Oncol Lett. 2018;16:483–90. https://doi.org/10.3892/ol.2018.8644.

[-]

recommendations

 

This item appears in the following Collection(s)

Show full item record